Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Definium Therapeutics, Inc. (DFTX : NSDQ)

• Company Description    Definium Therapeutics, Inc. is developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Definium Therapeutics Inc., formerly known as Mind Medicine Inc., is based in NEW YORK. Number of Employees: 74

• Price / Volume Information    Yesterday's Closing Price: $17.38 Daily Weekly Monthly 20 Day Moving Average: 1,624,955 shares Shares Outstanding: 98.51 (millions) Market Capitalization: $1,712.09 (millions) Beta: 2.57 52 Week High: $18.70 52 Week Low: $4.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.34% 1.26% 12 Week 43.64% 42.20% Year To Date 29.80% 29.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE WORLD TRADE CENTER SUITE 8500 - NEW YORK,NY 10007 USA ph: 212-220-6633 fax: - ir@mindmed.co http://www.mindmed.co

• General Corporate Information    Officers Robert Barrow - Chief Executive Officer and Director Carrie F. Liao - Chief Accounting Officer Carol Vallone - Director David Gryska - Director Roger Crystal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 24477V105 SIC: 2833 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/05/26 Share - Related Items Shares Outstanding: 98.51 Most Recent Split Date: 8.00 (0.07:1) Beta: 2.57 Market Capitalization: $1,712.09 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.43 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.73 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 10.22 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -188.89% vs. Previous Quarter: -56.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -86.18 06/30/25 - -50.24 ROA 12/31/25 - - 09/30/25 - -62.29 06/30/25 - -39.41 Current Ratio 12/31/25 - - 09/30/25 - 3.30 06/30/25 - 4.98 Quick Ratio 12/31/25 - - 09/30/25 - 3.30 06/30/25 - 4.98 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 1.70 06/30/25 - 2.44 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.31 06/30/25 - 0.22 Debt-to-Capital 12/31/25 - - 09/30/25 - 23.62 06/30/25 - 18.18

Powered by Zacks Investment Research ©